Guggenheim lowered the firm’s price target on AstraZeneca to 11,900 GBp from 12,700 GBp and keeps a Buy rating on the shares as the firm updates forecasts ahead of Q1 earnings for companies in its global biopharma coverage. Q1 for AstraZeneca will likely be "not as bad as feared," but the stock’s performance from here hinges on clinical catalysts, the analyst tells investors.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on AZN:
- AstraZeneca updates arrangements with Sobi, Sanofi for nirsevimab in U.S.
- AstraZeneca upgraded to Overweight from Equal Weight at Morgan Stanley
- GSK unit ordered to pay AstraZeneca royalties on Zejula sales, Reuters says
- AstraZeneca says Lynparza/Imfinzi combo met endpoint in ovarian cancer study
- Arvinas appoints Page as SVP, Global Head of Oncology Strategy, Program Leader